Percutaneous patent foramen ovale (PFO) closure in addition to medical therapy reduces the risk of recurrent cryptogenic stroke by 60% compared with medical therapy alone, according to a meta-analysis ...

The PREMIUM trial, which failed to show a benefit of patent foramen ovale (PFO) closure in patients with frequent migraines, is now in print. Responding to the publication this week, proponents of the ...

For years, members of the medical device industry have eyed patent foramen ovale (PFO) closure as a way to prevent strokes. Despite skepticism around the effectiveness of some of the candidate devices ...

Abbott has launched its Amplatzer Tailsman PFO Occlosion System in Europe. The device is designed to treat people with a patent foramen ovale (PFO) who have had a stroke and are at risk of having ...

Abbott Laboratories ABT recently launched its Amplatzer Talisman PFO Occlusion System in Europe. The Talisman device aims to treat patent foramen ovale (PFO) patients who have had a stroke and are at ...

Abbott Laboratories ABT recently received FDA approval for its Amplatzer Talisman PFO Occlusion System to treat patent foramen ovale (PFO) patients at risk of recurrent ischemic stroke. The ...

Patients with migraine, patent foramen ovale (PFO), and atrial septal aneurysm (ASA) have more frequent ischemic brain lesions, migraine with aura, and larger PFO sizes than patients with migraines ...